Interventional Lung Solutions Market Report 2025

The interventional lung solutions market size has grown strongly in recent years. It will grow from $2.3 billion in 2024 to $2.47 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to the increasing prevalence of respiratory diseases, the growing number of smokers worldwide, rising air pollution levels, increasing healthcare awareness, and the growing number of lung cancer cases.

The interventional lung solutions market size is expected to see strong growth in the next few years. It will grow to $3.39 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to growing adoption of telemedicine and remote monitoring, increasing focus on personalized medicine, increasing popularity of robotic-assisted surgery, growing adoption of minimally invasive procedures, and increasing focus on precision medicine. Major trends in the forecast period include developing lung cancer interventions, integrating artificial intelligence in bronchoscopy systems, integrating interventional pulmonology with oncology treatments, integrating digital platforms for lung disease management, and innovating lung regeneration therapies.

The forecast of 8.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade restrictions could burden pulmonology centers by driving up prices of bronchoscopic lung volume reduction systems manufactured in the Netherlands and Israel, exacerbating chronic obstructive pulmonary disease treatment expenses and increasing interventional pulmonology service costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of respiratory diseases is expected to significantly drive the expansion of the interventional lung solutions market in the coming years. Respiratory diseases encompass a range of medical conditions that affect the lungs and airways, impairing breathing and disrupting normal respiratory function. The increase in respiratory diseases is largely attributed to rising levels of air pollution, which contribute to prolonged exposure to harmful airborne particles and irritants. Interventional lung solutions assist in managing these diseases by providing minimally invasive procedures that improve lung function and alleviate symptoms in patients with chronic pulmonary conditions. For example, in November 2023, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported approximately 8,331 tuberculosis cases in the United States in 2022, marking a 5.9% increase from the previous year. This growing prevalence of respiratory diseases is driving the growth of the interventional lung solutions market.

Key players in the interventional lung solutions market are focusing on the development of cutting-edge technologies, such as the Ion Endoluminal System, to enhance the accuracy of lung cancer diagnostics, enable minimally invasive procedures, and improve patient outcomes through advanced navigation and biopsy capabilities. The Ion Endoluminal System is a robotic-assisted platform designed for minimally invasive lung procedures, enabling precise airway navigation to access small or difficult-to-reach lung nodules. For example, in April 2024, the H. Lee Moffitt Cancer Center and Research Institute Foundation Inc., a US-based non-profit organization, launched a new Ion Robotic Bronchoscopy platform to enhance their interventional pulmonology program with advanced fiber-optic technology and a minimally invasive catheter system. This technology employs fiber optics and the smallest catheter available on the market to access all areas of the lungs. It features an ultra-thin, highly maneuverable catheter with 180° articulation, integrated real-time vision, and shape-sensing technology, enabling precise navigation and biopsy of peripheral lung nodules that are difficult to reach. This system offers unprecedented stability and accuracy for tissue sampling, enabling physicians to reach all 18 lung segments, thus improving the detection of early-stage lung cancer.

In February 2025, Stryker Corporation, a US-based medical device company, acquired Inari Medical Inc. for an undisclosed amount. This acquisition is aimed at strengthening Stryker's interventional endovascular portfolio by adding innovative thrombolytic-free solutions for treating venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. Inari Medical Inc., based in the US, specializes in providing interventional solutions for pulmonary conditions, with a particular focus on treating pulmonary embolism (PE).

Major players in the interventional lung solutions market are Johnson and Johnson, Siemens AG, Medtronic plc, FUJIFILM Holdings Corporation, GE Healthcare Technologies Inc., Boston Scientific Corporation, Olympus Corporation, Intuitive Surgical Inc., Smiths Medical Inc., Cook Medical Inc., Merit Medical Systems Inc., Penumbra Inc., Vygon SA, AngioDynamics Inc., Vapotherm Inc., Pulmonx Corporation, Broncus Medical Inc., Thirona B.V., Body Vision Medical Ltd., The Lung Docs Inc., EndoMed Systems GmbH.

North America was the largest region in the interventional lung solutions market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interventional lung solutions report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the interventional lung solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The interventional lung solutions market consists of revenues earned by entities by providing services such as endobronchial valve placement, navigational bronchoscopy, lung volume reduction, and airway stenting. The market value includes the value of related goods sold by the service provider or included within the service offering. The interventional lung solutions market also consists of sales of products including bronchial thermoplasty devices, cryotherapy devices, bronchial stents, and biopsy forceps. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The interventional lung solutions market research report is one of a series of new reports that provides interventional lung solutions market statistics, including the interventional lung solutions industry's global market size, regional shares, competitors with the interventional lung solutions market share, detailed interventional lung solutions market segments, market trends and opportunities, and any further data you may need to thrive in the interventional lung solutions market. This interventional lung solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Interventional lung solutions refer to minimally invasive procedures and technologies designed to diagnose and treat lung conditions such as chronic obstructive pulmonary disease (COPD), lung cancer, and emphysema. These solutions typically include interventions such as bronchoscopy, endobronchial valves, and image-guided therapies, all aimed at improving lung function and enhancing patient outcomes.

The main types of interventional lung solutions include bronchoscopes, endobronchial ultrasound needles, pleuroscopes, airway stents, and other related devices. Bronchoscopes are medical instruments used to visualize and examine the airways and lungs, typically inserted through the nose or mouth to diagnose and treat respiratory conditions. Technologies associated with bronchoscopes include robotic surgery, laser therapy, and electromagnetic navigation bronchoscopy. The procedures involved include bronchoscopy, thoracoscopy, pleuroscopy, and others. These solutions are applied in various medical fields such as lung cancer treatment, COPD management, and sleep apnea treatment, and are used by a variety of end-users, including hospitals, ambulatory surgical centers, specialty clinics, and other healthcare settings.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.